Publications (23) View all
-
Article: Selection of Nanobodies that Target Human Neonatal Fc Receptor
J. T. Andersen, M. Gonzalez-Pajuelo, S. Foss, O. J. Landsverk, D. Pinto, A. Szyroki, H. J. de Haard, M. Saunders, P. Vanlandschoot, I. Sandlie[show abstract] [hide abstract]
ABSTRACT: FcRn is a key player in several immunological and non-immunological processes, as it mediates maternal-fetal transfer of IgG, regulates the serum persistence of IgG and albumin, and transports both ligands between different cellular compartments. In addition, FcRn enhances antigen presentation. Thus, there is an intense interest in studies of how FcRn binds and transports its cargo within and across several types of cells, and FcRn detection reagents are in high demand. Here we report on phage display-selected Nanobodies that target human FcRn. The Nanobodies were obtained from a variable-domain repertoire library isolated from a llama immunized with recombinant human FcRn. One candidate, Nb218-H4, was shown to bind FcRn with high affinity at both acidic and neutral pH, without competing ligand binding and interfering with FcRn functions, such as transcytosis of IgG. Thus, Nb218-H4 can be used as a detection probe and as a tracker for visualization of FcRn-mediated cellular transport.Scientific Reports 01/2013; 3:1118. -
SourceAvailable from: Gestur Vidarsson
Dataset: stapleton 2011 supplemental ncomms1608-s1
Nigel M Stapleton, Jan Terje Andersen, Annette M Stemerding, Stefania P Bjarnarson, Ruurd C Verheul, Jacoline Gerritsen, Yixian Zhao, Marion Kleijer, Inger Sandlie, Masja de Haas, Ingileif Jonsdottir, C Ellen van der Schoot, Gestur Vidarsson -
Article: Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, Aglycosylated IgG Displaying High FcγRIIa Affinity and Selectivity.
Sang Taek Jung, William Kelton, Tae Hyun Kang, Daphne T W Ng, Jan Terje Andersen, Inger Sandlie, Casim A Sarkar, George Georgiou[show abstract] [hide abstract]
ABSTRACT: Glycans anchored to residue N297 of the antibody IgG Fc domain are critical in mediating binding toward FcγRs to direct both adaptive and innate immune responses. However, using a full length bacterial IgG display system, we have isolated aglycosylated Fc domains with mutations that confer up to a 160-fold increase in the affinity toward the low affinity FcγRIIa-R131 allele as well as high selectivity against binding to the remarkably homologous human inhibitory receptor, FcγRIIb. The mutant Fc domain (AglycoT-Fc1004) contained a total of 5 amino acid substitutions that conferred an activating to inhibitory ratio of 25 (A/I ratio; FcyRIIa-R131:FcγRIIb). Incorporation of this engineered Fc into trastuzumab, an anti-Her2 antibody, resulted in a 75% increase in tumor cell phagocytosis by macrophages compared to that of the parental glycosylated trastuzumab with both medium and low Her2-expressing cancer cells. A mathematical model has been developed to help explain how receptor affinity and the A/I ratio relate to improved antibody dependent cell-mediated phagocytosis. Our model provides guidelines for the future engineering of Fc domains with enhanced effector function.ACS Chemical Biology 10/2012; · 6.45 Impact Factor -
Article: Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.
Jan Terje Andersen, Stian Foss, Vania E Kenanova, Tove Olafsen, Ingvild S Leikfoss, Derry C Roopenian, Anna M Wu, Inger Sandlie[show abstract] [hide abstract]
ABSTRACT: Serum half-life of IgG is controlled by the neonatal Fc receptor (FcRn) that interacts with the IgG Fc region and may be increased or decreased as a function of altered FcRn binding. Preclinical evaluations of modified IgGs are frequently carried out in mice, but such IgGs may bind differently to mouse and human FcRn (mFcRn and hFcRn). Here, we report a detailed characterization of a matched set of mouse-human chimeric T84.66 scFv-Fc variants with specificity for the tumor carcinoembryonic antigen and mutations in the FcRn-binding site. Binding to soluble mFcRn and hFcRn was measured using in vitro assays, and the results were compared with blood clearance in vivo in normal (mFcRn bearing) and hFcRn transgenic mice. All variants bound better to mFcRn than to hFcRn. The loss of affinity varied among the mutants, however, and also the hierarchy of binding differed depending on the receptor. The mutations had no major impact on binding to the classical Fcγ receptors. Importantly, the trend of blood clearance in both strains of mice correlated with the hierarchy of binding obtained using soluble FcRn. Consequently, in vitro interaction analysis of engineered IgGs regarding their cross-species FcRn binding ability provides information for prediction of in vivo pharmacokinetics.Journal of Biological Chemistry 05/2012; 287(27):22927-37. · 4.77 Impact Factor -
SourceAvailable from: Jan Terje Andersen
Article: Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.
Jan Terje Andersen, Bjørn Dalhus, Jason Cameron, Muluneh Bekele Daba, Andrew Plumridge, Leslie Evans, Stephan O Brennan, Kristin Støen Gunnarsen, Magnar Bjørås, Darrell Sleep, Inger Sandlie[show abstract] [hide abstract]
ABSTRACT: Albumin is the most abundant protein in blood where it has a pivotal role as a transporter of fatty acids and drugs. Like IgG, albumin has long serum half-life, protected from degradation by pH-dependent recycling mediated by interaction with the neonatal Fc receptor, FcRn. Although the FcRn interaction with IgG is well characterized at the atomic level, its interaction with albumin is not. Here we present structure-based modelling of the FcRn-albumin complex, supported by binding analysis of site-specific mutants, providing mechanistic evidence for the presence of pH-sensitive ionic networks at the interaction interface. These networks involve conserved histidines in both FcRn and albumin domain III. Histidines also contribute to intramolecular interactions that stabilize the otherwise flexible loops at both the interacting surfaces. Molecular details of the FcRn-albumin complex may guide the development of novel albumin variants with altered serum half-life as carriers of drugs.Nature Communications 01/2012; 3:610. · 7.40 Impact Factor